跳至主要内容
临床试验/ISRCTN61794329
ISRCTN61794329已完成不适用

Effects of oral N-acetyl-cysteine (NAC) in the early phase of schizophrenia spectrum psychosis: a randomised parallel double-blind placebo-controlled trial

Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland)0 个研究点目标入组 40 人开始时间: 2009年10月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Capability to provide informed consent
  • 2. Male or female aged 15 to 35 years with sufficient command of French language
  • 3. Having met threshold criteria for psychosis as defined by the Psychosis threshold subscale of the Comprehensive Assessment of at Risk Mental States Scale (CAARMS). This threshold is based on a combination of intensity and duration of psychotic symptoms.

排除标准

  • 1. Severe somatic comorbidities: peptic ulcer disease, chronic inflammatory pathologies, infectious pathologies including human immunodeficiency virus (HIV), pathologies of the immune system, organic cerebral diseases, tumours, abnormal renal, hepatic, thyroid or haematological findings
  • 2. Previous cerebral trauma
  • 3. Substance induced psychosis or organic psychosis
  • 4. Mental retardation (intellectual quotient [IQ] less than 70 and alteration or significant adaptation deficit). We will assess the IQ only in the case of necessity when we doubt about the intellectual skills of a patient.
  • 5. NAC allergy
  • 6. Treatment with antioxidants (vitamin E, selenium, multivitamins, etc.)
  • 7. Insufficient command of French

研究者

发起方
Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland)

相似试验